Grifols Partners with IBL to Target Neurology and Oncology Diagnostics

• Grifols has announced a strategic partnership with IBL International GmbH to expand its presence in the clinical diagnostics market.

• The collaboration will focus on developing ultra-sensitive, multiplexed assays targeting neurological and oncological biomarkers.

Grifols has entered a strategic partnership with IBL International GmbH to advance its presence in the clinical diagnostics sector. The agreement aims to bring high-sensitivity, multiplex diagnostic tools to laboratories, combining Grifols’ proprietary technology with IBL’s specialty assays.

The collaboration will utilise Grifols’ single molecule counting (SMC) technology, which enables ultra-sensitive detection and efficient multiplexing. This approach supports random-access operation, allowing labs to run individual analytes and assay types in any order, improving throughput and operational efficiency.

The initial focus will be on biomarker panels for neurological and oncological conditions. According to the press release, early disease signals may be identified more effectively using Grifols’ technology, potentially aiding timely intervention. Multiplex panels may also enhance diagnostic precision in cases involving multivariate biomarkers.

Grifols’ diagnostics portfolio already includes products such as Promonitor® for monitoring biologic therapies and AlphaID™, a genetic test for alpha-1 antitrypsin deficiency. Since launching AlphaID™ At Home in 2023, around 75,000 orders have been placed in the United States.

“Our revolutionary platform combining multiplexing and ultrasensitive single molecule counting technology is unique for in-vitro diagnostics,” said Antonio Martinez, President of Grifols Diagnostic Business Unit. The agreement includes frameworks for product development, manufacturing and commercialisation to ensure efficient delivery to the market.